SUPN — Supernus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.30bn
- $1.93bn
- $718.95m
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease
Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada
Supernus Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Supernus Pharmaceuticals Q3 Product Sales USD 170.3 Million
Brief: Supernus Pharmaceuticals Releases New Data From Phase 2A Study Of Spn-820
Brief: Supernus Announces Promising Data From Open-Label Phase 2A Study Of Spn-820 In Adults With Major Depressive Disorder
Brief: Busy Philipps Encourages Women To Take Charge Of Their Adhd This Fall In Ongoing Collaboration With Supernus Pharmaceuticals And Qelbree
Brief: Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted For Review By FDA
Supernus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Supernus Pharmaceuticals Q2 Product Sales USD 162.5 Million
Supernus Pharmaceuticals Inc expected to post earnings of 39 cents a share - Earnings Preview
Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Supernus Pharmaceuticals Q1 Adjusted Operating Earnings USD 22.3 Million Vs. IBES Estimate USD 22.9 Million
Supernus Pharmaceuticals Inc expected to post earnings of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Perpetua Resources, Huntington Bancshares, FuelCell Energy
U.S. STOCKS ON THE MOVE-JPMorgan, Ameresco, Copper miners
U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Brief: US FDA Declines To approve Supernus' Drug-device Combination For Parkinson's Disease
Supernus down as FDA declines nod to its Parkinson's disease drug-device combo